Effect of C-peptide on Hypoglycemic Counterregulation

Launched by UNIVERSITY OF CINCINNATI · Jun 17, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how a protein called C-peptide can help improve the body's response to low blood sugar (hypoglycemia) in individuals with type 1 diabetes. People with this condition often experience low blood sugar due to too much insulin, which can make it difficult for their bodies to release a hormone called glucagon that helps raise blood sugar levels. The researchers previously found that C-peptide can boost glucagon secretion in dogs and are now looking to see if the same effect occurs in humans.

To participate in this study, you need to be between the ages of 18 and 65 and have a body mass index (BMI) of less than 30. Unfortunately, pregnant or breastfeeding women, people who smoke, or those with certain health conditions like HIV, hepatitis, or heart and blood vessel diseases cannot join. If you take part, you'll help researchers understand how C-peptide might support better management of blood sugar levels, which could lead to safer treatments for people living with type 1 diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI less than 30 kg/m2
• Exclusion Criteria:
• • pregnant or lactating women cigarette smoking presence of HIV or hepatitis presence of cardiovascular disease presence of microvascular disease